Pacira BioSciences, Inc.
NASDAQ:PCRXDrug Manufacturers - Specialty & Generic
-$0.18 today
- Market cap
- $1.46B
- Beta
- 0.29
- P/E (TTM)
- 176.9
- EPS (TTM)
- $0.13
Volume 1.81M
Average 0.57M
PCRX Pre-Tax Margin
Income before tax as a percentage of revenue.
Pacira BioSciences, Inc.NASDAQ: PCRX
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin narrows to 2.8%
Pre-tax margin was 2.8% in Q1 FY2026, down 2.3 pp from a year earlier. On a trailing-twelve-month basis it was 1.8%, up 11.5 pp year over year. Over 3 fiscal years it widened by 0.3 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 2.3%
- Year-over-year change
- +11.3pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.3% | +11.3pp |
| FY2024 | 2024-12-31 | -9.0% | -18.1pp |
| FY2023 | 2023-12-31 | 9.1% | +7.1pp |
| FY2022 | 2022-12-31 | 2.0% | -8.4pp |
| FY2021 | 2021-12-31 | 10.4% | — |
Pre-Tax Margin vs competitors
How PCRX compares with its peers on the latest reported figures
- PCRX's LTM Mar 2026 pre-tax margin of 1.8% is the 2nd highest of the 4 companies compared; the peer median is -14.9%.
- Its year-over-year change of +11.5 pp is the highest of 4, against a peer median of -27.2 pp.
- Over three fiscal years its change of +0.3 pp compares with a peer median of -15.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 13.6% | +3.8 pp | +18.1 pp | |
| LTM Mar 2026 | 1.8% | +11.5 pp | +0.3 pp | |
| LTM Jun 2026 | -14.9% | -27.2 pp | -15.9 pp | |
| LTM Mar 2026 | -1162.4% | -1015.4 pp | -1174.9 pp | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — |
| Peer median (excluding PCRX) | -14.9% | -27.2 pp | -15.9 pp | |
Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 541.53M | 666.82M | 674.98M | 700.97M | 726.41M |
| Cost of Revenue | 140.26M | 199.3M | 184.67M | 170.43M | 149.75M |
| Gross Profit | 401.28M | 467.53M | 490.31M | 530.54M | 576.66M |
| Gross Margin | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% |
| Research & Development | 55.55M | 84.8M | 76.26M | 81.58M | 117.31M |
| Selling, General & Admin | 199.35M | 254.52M | 269.44M | 294.1M | 368.76M |
| Operating Expenses | 311.35M | 407.5M | 402.63M | 603.91M | 543.36M |
| Depreciation & Amortization | 28.55M | 91.5M | 75.57M | 78.79M | 91.02M |
| EBITDA | 113.95M | 140.38M | 154.59M | 29.12M | 122.5M |
| EBITDA Margin | 21.0% | 21.1% | 22.9% | 4.2% | 16.9% |
| Operating Income | 89.92M | 60.02M | 87.68M | (73.37M) | 33.3M |
| Operating Margin | 16.6% | 9.0% | 13.0% | -10.5% | 4.6% |
| Interest Income | 896K | 4.54M | 11.44M | 19.69M | 22.73M |
| Interest Expense | 29M | 35.58M | 17.31M | 16.57M | 14.61M |
| Other Income / Expenses | (33.52M) | (46.72M) | (25.97M) | 10.27M | (16.43M) |
| Income Before Tax | 56.4M | 13.3M | 61.7M | (63.11M) | 16.87M |
| Pre-Tax Margin | 10.4% | 2.0% | 9.1% | -9.0% | 2.3% |
| Income Tax Expense | 14.42M | (2.61M) | 19.75M | 36.45M | 9.84M |
| Net Income | 41.98M | 15.91M | 41.96M | (99.56M) | 7.03M |
| Net Margin | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
| EPS (Basic) | 0.95 | 0.35 | 0.91 | (2.15) | 0.16 |
| EPS (Diluted) | 0.92 | 0.34 | 0.89 | (2.15) | 0.16 |
| Weighted Avg Shares | 44.26M | 45.52M | 46.22M | 46.25M | 44.57M |
| Weighted Avg Shares (Diluted) | 45.63M | 46.54M | 51.98M | 46.25M | 45.04M |
Pacira BioSciences, Inc.
NASDAQ:PCRX
Intrinsic Alpha fair value
Locked
Current Price
$36.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.